Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2003 2
2005 1
2008 2
2015 1
2017 1
2018 3
2021 1
2022 0
Text availability
Article attribute
Article type
Publication date

Search Results

10 results
Results by year
Filters applied: . Clear all
Page 1
Collections dā€™Ć©chantillons biologiques humains pour la rechercheĀ : principaux enjeux et consĆ©quences pour le patientĀ ?
Verstuyft C, Antoun Z, Deplanque D; les participants Ć  la table ronde Ā«Ā Recherche clinique et mĆ©thodologieĀ Ā» des Ateliers de Giens XXXIII. Verstuyft C, et al. Among authors: antoun z. Therapie. 2018 Feb;73(1):63-72. doi: 10.1016/j.therap.2017.12.003. Epub 2017 Dec 19. Therapie. 2018. PMID: 29433746 French. No abstract available.
Efficacy and safety of once-daily fluticasone furoate/vilanterol (FF/VI) versus twice-daily inhaled corticosteroids/long-acting Ī²2-agonists (ICS/LABA) in patients with uncontrolled asthma: An open-label, randomized, controlled trial.
Devillier P, Humbert M, Boye A, Zachgo W, Jacques L, Nunn C, West S, Nicholls A, Antoun Z, Spinu L, Grouin JM. Devillier P, et al. Among authors: antoun z. Respir Med. 2018 Aug;141:111-120. doi: 10.1016/j.rmed.2018.06.009. Epub 2018 Jun 9. Respir Med. 2018. PMID: 30053956 Free article. Clinical Trial.
Clinically validated mutation scores for HIV-1 resistance to fosamprenavir/ritonavir.
Masquelier B, Assoumou KL, Descamps D, Bocket L, Cottalorda J, Ruffault A, Marcelin AG, Morand-Joubert L, Tamalet C, Charpentier C, Peytavin G, Antoun Z, Brun-VĆ©zinet F, Costagliola D; ANRS Resistance Study Group. Masquelier B, et al. Among authors: antoun z. J Antimicrob Chemother. 2008 Jun;61(6):1362-8. doi: 10.1093/jac/dkn127. Epub 2008 Apr 4. J Antimicrob Chemother. 2008. PMID: 18390885
Genotypic resistance analysis of the virological response to fosamprenavir-ritonavir in protease inhibitor-experienced patients in CONTEXT and TRIAD clinical trials.
Marcelin AG, Flandre P, Molina JM, Katlama C, Yeni P, Raffi F, Antoun Z, Ait-Khaled M, Calvez V. Marcelin AG, et al. Among authors: antoun z. Antimicrob Agents Chemother. 2008 Dec;52(12):4251-7. doi: 10.1128/AAC.00514-08. Epub 2008 Oct 13. Antimicrob Agents Chemother. 2008. PMID: 18852278 Free PMC article. Clinical Trial.
Comparison of metabolic abnormalities 48 weeks after switching from highly active antiretroviral therapy containing a non-nucleoside reverse transcriptase inhibitor to Trizivir versus continued highly active antiretroviral therapy.
Katlama C, Gazzard B, Mallolas J, SchĆ¼rmann D, Moroni M, Demonty N, Antoun Z, Gordon D. Katlama C, et al. Among authors: antoun z. AIDS. 2003 Aug 15;17(12):1855-6. doi: 10.1097/00002030-200308150-00017. AIDS. 2003. PMID: 12891074 Clinical Trial.
Comparison of metabolic abnormalities and clinical lipodystrophy 48 weeks after switching from HAART to Trizivir versus continued HAART: the Trizal study.
Lafeuillade A, Clumeck N, Mallolas J, Jaeger H, Livrozet JM, Ferreira Mdo S, Johnson M, Cheret A, Antoun Z; European Trizal team. Lafeuillade A, et al. Among authors: antoun z. HIV Clin Trials. 2003 Jan-Feb;4(1):37-43. doi: 10.1310/ejrf-jggh-grcd-med8. HIV Clin Trials. 2003. PMID: 12577195 Clinical Trial.